BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36111424)

  • 1. Special issue "The advance of solid tumor research in China": Prediction of Sunitinib efficacy using computed tomography in patients with pancreatic neuroendocrine tumors.
    Chen L; Wang W; Jin K; Yuan B; Tan H; Sun J; Guo Y; Luo Y; Feng ST; Yu X; Chen MH; Chen J
    Int J Cancer; 2023 Jan; 152(1):90-99. PubMed ID: 36111424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maximum Value on Arterial Phase Computed Tomography Predicts Prognosis and Treatment Efficacy of Sunitinib for Pancreatic Neuroendocrine Tumours.
    Chen H; Li Z; Hu Y; Xu X; Ye Z; Lou X; Zhang W; Gao H; Qin Y; Zhang Y; Chen X; Chen J; Tang W; Yu X; Ji S
    Ann Surg Oncol; 2023 May; 30(5):2988-2998. PubMed ID: 36310316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response.
    Lamarca A; Barriuso J; Kulke M; Borbath I; Lenz HJ; Raoul JL; Meropol NJ; Lombard-Bohas C; Posey J; Faivre S; Raymond E; Valle JW
    Br J Cancer; 2018 Jan; 118(2):181-188. PubMed ID: 29161241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accurate non-invasive grading of nonfunctional pancreatic neuroendocrine tumors with a CT derived radiomics signature.
    Javed AA; Zhu Z; Kinny-Köster B; Habib JR; Kawamoto S; Hruban RH; Fishman EK; Wolfgang CL; He J; Chu LC
    Diagn Interv Imaging; 2024 Jan; 105(1):33-39. PubMed ID: 37598013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study).
    Solis-Hernandez MP; Fernandez Del Valle A; Carmona-Bayonas A; Garcia-Carbonero R; Custodio A; Benavent M; Alonso Gordoa T; Nuñez-Valdovino B; Sanchez Canovas M; Matos I; Alonso V; Lopez C; Viudez A; Izquierdo M; Calvo-Temprano D; Grande E; Capdevila J; Jimenez-Fonseca P
    Br J Cancer; 2019 Oct; 121(7):537-544. PubMed ID: 31477779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A preoperative computed tomography radiomics model to predict disease-free survival in patients with pancreatic neuroendocrine tumors.
    Homps M; Soyer P; Coriat R; Dermine S; Pellat A; Fuks D; Marchese U; Terris B; Groussin L; Dohan A; Barat M
    Eur J Endocrinol; 2023 Oct; 189(4):476-484. PubMed ID: 37787635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Combined Nomogram Model to Preoperatively Predict Histologic Grade in Pancreatic Neuroendocrine Tumors.
    Liang W; Yang P; Huang R; Xu L; Wang J; Liu W; Zhang L; Wan D; Huang Q; Lu Y; Kuang Y; Niu T
    Clin Cancer Res; 2019 Jan; 25(2):584-594. PubMed ID: 30397175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CT radiomics may predict the grade of pancreatic neuroendocrine tumors: a multicenter study.
    Gu D; Hu Y; Ding H; Wei J; Chen K; Liu H; Zeng M; Tian J
    Eur Radiol; 2019 Dec; 29(12):6880-6890. PubMed ID: 31227882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CT-based radiomics for prediction of therapeutic response to Everolimus in metastatic neuroendocrine tumors.
    Caruso D; Polici M; Rinzivillo M; Zerunian M; Nacci I; Marasco M; Magi L; Tarallo M; Gargiulo S; Iannicelli E; Annibale B; Laghi A; Panzuto F
    Radiol Med; 2022 Jul; 127(7):691-701. PubMed ID: 35717429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study.
    Ito T; Tori M; Hashigaki S; Kimura N; Sato K; Ohki E; Sawaki A; Okusaka T
    Jpn J Clin Oncol; 2019 Apr; 49(4):354-360. PubMed ID: 30834940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of CT-based radiomics in grade 1-2 pancreatic neuroendocrine tumors.
    Heo S; Park HJ; Kim HJ; Kim JH; Park SY; Kim KW; Kim SY; Choi SH; Byun JH; Kim SC; Hwang HS; Hong SM
    Cancer Imaging; 2024 Feb; 24(1):28. PubMed ID: 38395973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors.
    Gao H; Dong J; Zhang W; Xu H; Ye L; Li H; Ni Q; Wang W; Liu L
    Endocr Pract; 2022 Mar; 28(3):292-297. PubMed ID: 34454077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative contrast-enhanced computed tomography-based radiomics model for overall survival prediction in hepatocellular carcinoma.
    Deng PZ; Zhao BG; Huang XH; Xu TF; Chen ZJ; Wei QF; Liu XY; Guo YQ; Yuan SG; Liao WJ
    World J Gastroenterol; 2022 Aug; 28(31):4376-4389. PubMed ID: 36159012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CT-based radiomics signature of visceral adipose tissue for prediction of disease progression in patients with Crohn's disease: A multicentre cohort study.
    Li X; Zhang N; Hu C; Lin Y; Li J; Li Z; Cui E; Shi L; Zhuang X; Li J; Lu J; Wang Y; Liu R; Yuan C; Lin H; He J; Ke D; Tang S; Zou Y; He B; Sun C; Chen M; Huang B; Mao R; Feng ST
    EClinicalMedicine; 2023 Feb; 56():101805. PubMed ID: 36618894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms.
    Mizuno Y; Kudo A; Akashi T; Akahoshi K; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Tanaka S; Tateishi U; Tanabe M
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1155-1163. PubMed ID: 29602973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours.
    Raymond E; Kulke MH; Qin S; Yu X; Schenker M; Cubillo A; Lou W; Tomasek J; Thiis-Evensen E; Xu JM; Croitoru AE; Khasraw M; Sedlackova E; Borbath I; Ruff P; Oberstein PE; Ito T; Jia L; Hammel P; Shen L; Shrikhande SV; Shen Y; Sufliarsky J; Khan GN; Morizane C; Galdy S; Khosravan R; Fernandez KC; Rosbrook B; Fazio N
    Neuroendocrinology; 2018; 107(3):237-245. PubMed ID: 29991024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Computed Tomography Radiomics Signature with Progression-free Survival in Neuroblastoma Patients.
    Wang H; Li T; Xie M; Si J; Qin J; Yang Y; Zhang L; Ding H; Chen X; He L
    Clin Oncol (R Coll Radiol); 2023 Nov; 35(11):e639-e647. PubMed ID: 37349199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative prediction for lauren type of gastric cancer: A radiomics nomogram analysis based on CT images and clinical features.
    Sun Z; Jin L; Zhang S; Duan S; Xing W; Hu S
    J Xray Sci Technol; 2021; 29(4):675-686. PubMed ID: 34024809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors.
    Lee L; Ito T; Igarashi H; Miki M; Fujimori N; Kawabe K; Jensen RT; Ogawa Y
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):163-169. PubMed ID: 29164297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of the characteristics of aggressiveness of pancreatic neuroendocrine neoplasms (PanNENs) based on CT radiomic features.
    Mori M; Palumbo D; Muffatti F; Partelli S; Mushtaq J; Andreasi V; Prato F; Ubeira MG; Palazzo G; Falconi M; Fiorino C; De Cobelli F
    Eur Radiol; 2023 Jun; 33(6):4412-4421. PubMed ID: 36547673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.